Table 2.

Studies of the Cost-Effectiveness of Treatment for ADHD

Citation	Comparators	Study Design	Findings1
Gilmore & Milne 2001	MPH, placebo	• Decision analytic model assessing cost-utility	Cost per each additional QALY gained with MPH treatment (versus no treatment) ranged from $15,509 to $19,281 when considering short-and medium-term benefits of MPH. Cost per QALY gained ranged from $9,850–$59,101 in sensitivity analyses
Novartis data on file (2000; referenced in Lord & Paisley 2000)	MPH, placebo	• Decision analytic model assessing cost-utility	Cost per each additional QALY gained with MPH treatment (versus no treatment) was $27,766.
Zupancic et al. 1998	MPH, placebo	• Decision analytic model assessing cost-effectiveness	Cost per each additional point in the Conners Teacher Rating Scale gained with MPH treatment (versus no treatment) was $93, or $560 for a 6-point (1 SD) gain.

¹All costs updated to Year 2004 US $ using the Medical Services component of the Consumer Price Index (for US-based studies). For non-US studies, all country-specific costs first updated to Year 2004 currency values based on country-specific inflators; and then converted to Year 2004 US$ based on currency exchange rates.

MPH = methylphenidate

QALY = quality-adjusted life years